Vetigenics is seeing encouraging results of a completed study for an antibody aimed at treating oral melanoma in dogs, used ...

Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly grow ...

Promising data have been obtained with the use of antibodies targeting vWF itself ... The improvement of our knowledge on the pharmacodynamics of antiplatelet drugs enables the tailoring of ...

Arvinas Inc. (ARVN) reported its earnings for the fourth quarter of 2024, revealing a smaller-than-expected loss per share ...

The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Based on continued emergence of bempikibart data from SIGNAL-AA Part A, including strong re-consent rates and patient demand for continued dosing, Company initiating open-label extension in 1H'25; ...

Introduction: While the prevalence of neurodegenerative diseases associated with dementia such as Alzheimer's disease (AD) increases, our knowledge on the underlying mechanisms, outcome predictors, or ...

CHATHAM, N.J. - Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a clinical-stage biotech company with a market capitalization of $28 million, announced today positive outcomes from its Phase 1 ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

Moreover, such engineered antibodies can also mediate Fc functions ... such amino acid sequence alterations can also alter the pharmacodynamics and pharmacokinetic characteristics of a therapeutic ...